PPARG and metabolic dysfunction-associated steatohepatitis: Genistein treatment could significantly reduce hepatic protein expression of PPARγ only in non-OVX rats (NASH vs. NASH+Gen; 1.01 ± 0.64 vs. 2.21 ± 0.68, respectively; p < 0.01).